ArticleJournal of cancer research and clinical oncology2026
Investigating the oncogenic potential of MTHFD2 in oral squamous cell carcinoma.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMethylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a mitochondrial bifunctional enzyme, is reportedly upregulated in several malignancies, demonstrating cancer-associated dysregulation. However, its functional contribution to oral squamous cell carcinoma (OSCC) progression remains unexplored. Therefore, this study aimed to investigate the role of MTHFD2 in OSCC development.
methodsMTHFD2 expression was assessed in OSCC biospecimens using integrated bioinformatics, immunohistochemistry, and immunoblotting techniques. Survival analysis was conducted utilizing the Kaplan–Meier methodology. The MTHFD2-associated mechanisms involved in OSCC were explored via enrichment analysis. Genetic suppression of MTHFD2 was employed to evaluate the functional consequences on OSCC cell proliferation (Cell Counting Kit-8 assay), apoptosis (flow cytometry), migration (wound healing assay), and invasion (Matrigel transmigration).
resultsMTHFD2 expression was considerably elevated in OSCC lesions and cellular models. MTHFD2 overexpression in OSCC tissues correlated with advanced Tumor, Node, and Metastasis stage (P = 0.002), regional lymph node metastasis (P = 0.043), and elevated Ki67 expression (P < 0.001). Furthermore, increased MTHFD2 levels were associated with poor overall survival outcomes in patients with OSCC (P < 0.05). Pathway enrichment analysis revealed that MTHFD2 upregulation was closely linked to the dysregulation of key neoplastic processes. Stable MTHFD2 depletion attenuated cell proliferation in vitro and diminished xenograft tumorigenicity in vivo (P < 0.05). Additionally, MTHFD2 ablation induced OSCC cell apoptosis and reduced cell migration and invasion.
conclusionThis study indicates that MTHFD2 is critical for OSCC progression and may serve as a potential therapeutic target, though further validation is needed to confirm its independent prognostic value and clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.